ADRX Andrx Group

NASDAQ
$14.00

Andrx Group (ADRX) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.36 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.4% since its last earnings release on November 12, 2026.

Andrx Group Missed Consensus Estimates
Thursday, November 12, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 6:10 PM ET
Earnings Whisper
-
vs ($0.36)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $14.09

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Andrx Group

Andrx Corp. formulates and commercializes controlled-release oral pharmaceuticals using their proprietary drug delivery technologies. Through Andrx Corp.'s distribution operations, they sell generic drugs manufactured by third parties primarily to pharmacies which do not maintain their own central warehousing facilities and pharmacy buying groups. Through their Cybear subsidiary, Andrx Corp. develops Internet applications to improve the efficiency of administrative and communications tasks for companies in health care industry.

Industry

Drug Delivery

Charts powered in part by Lightweight Charts™ by TradingView.